아릴 탄화수소 수용체(AHR) 작용제 : 시장 규모, 대상 환자층, 경쟁 구도 및 시장 예측(2036년)

Key Highlights:

• Aryl hydrocarbon receptor (AHR) signaling contributes to an immunosuppressive tumor microenvironment, making AHR inhibition an attractive strategy for restoring antitumor immune activity.
• Development is concentrated in advanced solid tumors, particularly urothelial/bladder cancer, head and neck cancer, melanoma, and other immune-resistant tumors.
• IK-175 is among the most clinically advanced AHR inhibitors: Clinical studies have demonstrated target engagement, a favorable safety profile, and preliminary antitumor activity in heavily pretreated urothelial carcinoma, including patients resistant to prior checkpoint inhibitors.
• Despite strong biological rationale, the AHR inhibitor landscape remains largely clinical/preclinical, with no established AHR inhibitor blockbuster or approved AHR antagonist driving the market today. The first successful late-stage program could therefore substantially reshape the competitive landscape.

DelveInsight's "Aryl Hydrocarbon Receptor Agonists Market Size, Target Population, Competitive Landscape & Market Forecast - 2036" report delivers an in-depth understanding of Aryl Hydrocarbon Receptor Agonists, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The Aryl Hydrocarbon Receptor Agonists market report provides insights around existing treatment practices in patients with Aryl Hydrocarbon Receptor Agonists, approved (if any) and emerging Aryl Hydrocarbon Receptor Agonists, market share of individual therapies, patient pool eligible for treatment with Aryl Hydrocarbon Receptor Agonists, along with current and forecasted 7MM Aryl Hydrocarbon Receptor Agonists market size from 2022-2036 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new Aryl Hydrocarbon Receptor Agonists in different geographies, along with insights on Aryl Hydrocarbon Receptor Agonists pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2022-2036

Aryl Hydrocarbon Receptor Agonists Overview

Aryl hydrocarbon receptor (AHR) inhibitors are a class of therapeutic agents designed to block or reduce the activity of the AHR, a ligand-activated transcription factor that regulates immune responses, inflammation, cell differentiation, and metabolism. AHR signaling can be activated by naturally occurring or disease-associated molecules, including tryptophan metabolites, leading to changes in gene expression. By inhibiting this pathway, AHR inhibitors aim to modulate abnormal immune and inflammatory activity and potentially restore immune balance. They are being investigated across several therapeutic areas, particularly cancer, autoimmune and inflammatory diseases, and other conditions where dysregulated AHR signaling may contribute to disease progression. Unlike conventional therapies that may target a specific cytokine or immune cell, AHR inhibitors offer a broader approach by interfering with a regulatory pathway that influences multiple downstream biological processes.

Aryl Hydrocarbon Receptor Agonists in Clinical Practice

This section will give in depth information about the existing local and systemic options in the current treatment paradigm of all the potential indications, in which most of the pharmaceutical companies are actively evaluating their inhibitors. Potential of the emerging Aryl Hydrocarbon Receptor Agonists in changing the current clinical practice guidelines is crucial to analyze especially when it comes to real world scenario.

It will also include the relevance and importance of incorporation of biomarker testing at varying stages of the disease. It is also important to understand that implementing such tests in routine clinical practice is not uniform in different countries due to issues such as cost, accessibility, reimbursement and non-recommendation in guidelines.

Target Patient Pool Analysis

• An estimated 84,530 new bladder cancer cases and 17,870 deaths are projected in the U.S. in 2026.
• Only 6% of bladder cancer cases are diagnosed at the distant/metastatic stage, where the 5-year relative survival is just 9.1%.
• Bladder cancer has an overall 79.1% five-year relative survival, but outcomes deteriorate dramatically once disease becomes metastatic.

Aryl Hydrocarbon Receptor Agonists Drug Chapters

The drug chapter segment of the Aryl Hydrocarbon Receptor Agonists report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the Aryl Hydrocarbon Receptor Agonists clinical trial details, pharmacological action, agreements and collaborations related to Aryl Hydrocarbon Receptor Agonists, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

Aryl Hydrocarbon Receptor Agonists Emerging Drugs

IK-175 - Ikena Oncology/Bristol Myers Squibb

IK-175 is an oral, selective AHR inhibitor designed to suppress AHR-mediated immunosuppression in tumors. Clinical development has focused particularly on urothelial carcinoma and other advanced solid tumors, including combinations with nivolumab. The program has shown evidence of target engagement and preliminary clinical activity.

BAY 2416964 - Bayer

BAY 2416964 is an oral AHR antagonist investigated in patients with advanced solid tumors, including non-small cell lung cancer and head and neck squamous cell carcinoma. Available reviews identify its Phase 1 study as completed in 2024.

Recent Developments in the AHR Inhibitors Market

• In May 2026, Equillium announced plans to host a virtual investor event focused on new insights into the aryl hydrocarbon receptor (AhR) and miR-124 axis. The company is exploring this pathway as a potential therapeutic mechanism, expanding interest in AhR-directed approaches beyond oncology.
• Research published in 2025 and discussed in subsequent literature identified IK-364 as a potent AHR inhibitor in preclinical development. Experimental studies showed suppression of AHR downstream signaling, including reduced CYP1B1 expression, supporting further investigation of AHR blockade in hematologic malignancies.
• At the 2024 ASCO meeting, investigators presented clinical data on IK-175 as monotherapy and in combination with nivolumab. IK-175 was described as a selective, orally administered small-molecule AHR inhibitor designed to modulate an immunosuppressive pathway in cancer.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on Aryl Hydrocarbon Receptor Agonists as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of Aryl Hydrocarbon Receptor Agonists, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

Aryl Hydrocarbon Receptor Agonists Market Outlook

This section will include details on changing Aryl Hydrocarbon Receptor Agonists market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

Aryl Hydrocarbon Receptor Agonists Drugs Uptake

This section focuses on the uptake rate of potential Aryl Hydrocarbon Receptor Agonists already launched and expected to be launched in the market during 2022-2036, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Aryl Hydrocarbon Receptor Agonists Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Aryl Hydrocarbon Receptor Agonists Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Aryl Hydrocarbon Receptor Agonists.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on Aryl Hydrocarbon Receptor Agonists' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on Aryl Hydrocarbon Receptor Agonists addressable patient pool
• A detailed review of the Aryl Hydrocarbon Receptor Agonists market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM Aryl Hydrocarbon Receptor Agonists market.
• Market Size of Inhibitors by therapies and indication will be provided

Aryl Hydrocarbon Receptor Agonists Report Key Strengths

• 11 Years Aryl Hydrocarbon Receptor Agonists Market Forecast
• The 7MM Coverage
• Aryl Hydrocarbon Receptor Agonists Competitive Landscape of current and emerging therapies
• Aryl Hydrocarbon Receptor Agonists Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician's perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• Aryl Hydrocarbon Receptor Agonists Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs:

• What was the Aryl Hydrocarbon Receptor Agonists total market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for Aryl Hydrocarbon Receptor Agonists market growth?
• Which AHR Inhibitor is going to be the largest contributor by 2036?
• What is the market access and reimbursement scenario of Aryl Hydrocarbon Receptor Agonists?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Aryl Hydrocarbon Receptor Agonists Market.
• Understand the existing Aryl Hydrocarbon Receptor Agonists market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Aryl Hydrocarbon Receptor Agonists

4. Key Events

5. Aryl Hydrocarbon Receptor Agonists Market Overview At A Glance

• 5.1. Market Share (%) Distribution of Aryl Hydrocarbon Receptor Agonists By Therapy in 2025
• 5.2. Market Share (%) Distribution of Aryl Hydrocarbon Receptor Agonists By Therapy in 2036

6. Background And Overview

7. Target Population

8. Aryl Hydrocarbon Receptor Agonists Marketed Drugs

• 8.1. Key Competitors
  • 8.1.1. Product Description
  • 8.1.2. Regulatory Milestones
  • 8.1.3. Other Developmental Activities
  • 8.1.4. Ongoing Clinical Development
  • 8.1.5. Safety and Efficacy

9. Aryl Hydrocarbon Receptor Agonists Emerging Drugs

• 9.1. Key Competitors
  • 9.1.1. Product Description
  • 9.1.2. Other Development Activities
  • 9.1.3. Clinical Development
    • 9.1.3.1. Clinical Trials Information
  • 9.1.4. Safety and Efficacy

10. Aryl Hydrocarbon Receptor Agonists: The 7MM Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Key Market Forecast Assumptions
• 10.4. Total Market Size of Aryl Hydrocarbon Receptor Agonists in the 7MM
  • 10.4.1. Market Size of Aryl Hydrocarbon Receptor Agonists By Therapies In the 7MM
  • 10.4.2. Market Size of Aryl Hydrocarbon Receptor Agonists By Indication In the 7MM
• 10.6. United States Market
  • 10.6.1. Total Market Size of Aryl Hydrocarbon Receptor Agonists in the United States
  • 10.6.2. Market Size of Aryl Hydrocarbon Receptor Agonists By Therapies in the United States
• 10.7. EU4 and the UK Market
  • 10.7.1. Total Market Size of Aryl Hydrocarbon Receptor Agonists in EU4 and the UK
  • 10.7.2. Market Size of Aryl Hydrocarbon Receptor Agonists By Therapies in EU4 and the UK
• 10.8. Japan Market
  • 10.8.1. Total Market Size of Aryl Hydrocarbon Receptor Agonists in Japan
  • 10.8.2. Market Size of Aryl Hydrocarbon Receptor Agonists By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

• 14.1. United States
  • 14.1.1. Centre for Medicare & Medicaid Services (CMS)
• 14.2. EU4 and the UK
  • 14.2.1. Germany
  • 14.2.2. France
  • 14.2.3. Italy
  • 14.2.4. Spain
  • 14.2.5. United Kingdom
• 14.3. Japan
  • 14.3.1. MHLW

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight